PGPEP1L Inhibitors
PGPEP1L inhibitors refer to a class of chemical compounds that specifically target and inhibit the activity of the pyroglutamyl-peptidase I-like (PGPEP1L) enzyme. PGPEP1L is involved in the hydrolysis of N-terminal pyroglutamyl residues from peptide chains, a modification commonly found in various biologically active peptides. The inhibition of this enzyme can alter the metabolism and degradation pathways of specific peptides, leading to changes in peptide stability and bioavailability. The activity of PGPEP1L is significant in the regulation of peptides that contain a pyroglutamic acid residue, which can influence their overall biological function and degradation rates. PGPEP1L inhibitors are designed to bind with high specificity to the active site of the enzyme, preventing the catalytic action that cleaves pyroglutamic acid groups from substrates. These inhibitors typically interact with the enzyme's catalytic domain, often utilizing structural features that mimic the enzyme's natural substrates to block its function.
Structurally, PGPEP1L inhibitors can vary widely depending on the specific chemistry involved in targeting the enzyme's active site. Many inhibitors are small molecules that are engineered to interact through key binding interactions, such as hydrogen bonding, van der Waals forces, and ionic interactions, with the amino acid residues present in the active site. The design of these inhibitors involves optimizing binding affinity and selectivity to ensure that the PGPEP1L enzyme is effectively and specifically inhibited, minimizing interaction with other enzymes or proteins. Researchers studying this class of compounds often focus on understanding the structural biology of PGPEP1L to design more potent inhibitors. This includes examining enzyme-inhibitor complexes through crystallography or molecular modeling to enhance the understanding of binding mechanisms and to develop inhibitors with greater specificity and stability.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bestatin | 58970-76-6 | sc-202975 | 10 mg | $131.00 | 19 | |
Bestatin inhibits aminopeptidases, disrupting the N-terminal processing of peptides. PGPEP1L, involved in pyroglutamyl-peptidase activity, relies on N-terminal cleavage for substrate processing, making Bestatin an indirect inhibitor by interfering with the precursor peptides' maturation. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 inhibits cysteine proteases, affecting various cellular processes. By targeting proteolytic pathways, E-64 indirectly influences PGPEP1L's function in proteolysis, disrupting its role in peptide processing within the cytosol. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin inhibits serine and cysteine proteases, impacting proteolytic pathways. PGPEP1L, involved in proteolysis, is indirectly inhibited by Leupeptin through modulation of these protease activities, disrupting the cellular processes associated with the target gene. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 inhibits the proteasome, altering protein degradation pathways. PGPEP1L's involvement in proteolysis is impacted by MG-132, as it disrupts the proteasomal function, indirectly influencing the degradation of substrates targeted by PGPEP1L. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin inhibits the proteasome, affecting protein degradation pathways. PGPEP1L, associated with proteolysis, is indirectly inhibited by Epoxomicin through interference with the proteasomal machinery, disrupting the degradation of substrates regulated by PGPEP1L. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, altering protein degradation pathways. PGPEP1L's role in proteolysis is indirectly inhibited by Bortezomib, as it disrupts the proteasomal function, influencing the degradation of substrates targeted by PGPEP1L. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
Nelfinavir inhibits HIV protease, affecting proteolytic pathways. PGPEP1L, involved in proteolysis, is indirectly impacted by Nelfinavir, as it disrupts specific protease activities, influencing the cellular processes associated with the target gene. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $121.00 $456.00 | 28 | |
Calpain Inhibitor I specifically inhibits calpains, affecting proteolytic pathways. PGPEP1L, engaged in proteolysis, is indirectly inhibited by Calpain Inhibitor I through interference with calpain activities, disrupting the cellular processes associated with the target gene. | ||||||
Phenylmethylsulfonyl Fluoride | 329-98-6 | sc-3597 sc-3597A | 1 g 100 g | $50.00 $697.00 | 92 | |
PMSF inhibits serine proteases, impacting proteolytic pathways. PGPEP1L, involved in proteolysis, is indirectly inhibited by PMSF as it disrupts specific protease activities, influencing the cellular processes associated with the target gene. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits proteasome activity and modulates multiple cellular pathways. PGPEP1L, associated with proteolysis, is indirectly inhibited by EGCG through interference with the proteasomal function and modulation of various pathways, impacting the cellular processes regulated by PGPEP1L. | ||||||